Biotek-snakken — Januar 2024
-
-
Alligator Bioscience Announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer – Alligator Bioscience
Top-line readout demonstrates Objective Response Rate of 40.4%, meeting primary endpoint and confirming the benefit of mitazalimab in combin ...
(alligatorbioscience.se)
-
PS: De er ved at afslutte et fase II-forsøg og har en aftale med FDA om et møde for opsætning af fase III-forsøg https://irlab.se/newsroom/pressrelease-archive/, men det i sig selv er vel ikke tilstrækkeligt til så stor en stigning?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind